Ruxolitinib versus basiliximab for steroid-refractory acute graft-versus-host disease: A retrospective study

Data from a retrospective analysis found that ruxolitinib was superior to basiliximab in the treatment of steroid-refractory acute GVHD. Patients in the ruxolitinib group had a higher overall response and complete response at day 28 compared with those in the basiliximab group (OR: 72.8% vs. 54.2%, respectively [P = 0.031]; CR: 58.0% vs. 35.4%, respectively [P = 0.013]). Ruxolitinib also demonstrated significantly lower 1-year cumulative incidence of chronic GVHD (29.6% vs. 43.8% [P = 0.021]).